RxDoctor Payments Data

Adam Grisak, MD

Family Medicine · Cincinnati, OHNPI 1881014645

Payments from drug & device makers

$10,405in general payments, 2019–2025

Across 553 payments — averaging $18.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Abbott$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$874
  • Lilly USA, LLC$706
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$10,405100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,405 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$45,754
Medicare patients
118
Services billed
559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$52,391
OzempicSemaglutide36$44,353
JardianceEmpagliflozin35$42,693
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$33,139
JanuviaSitagliptin Phosphate28$26,255
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$15,808
XareltoRivaroxaban22$15,374
Tresiba Flextouch U-200Insulin Degludec14$13,406
MounjaroTirzepatide12$12,813
Soliqua 100-33Insulin Glargine/Lixisenatide12$10,044
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,857
SymbicortBudesonide/Formoterol Fumarate16$6,122
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,726
Tresiba Flextouch U-100Insulin Degludec13$3,743
Albuterol Sulfate HfaAlbuterol Sulfate159$3,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$538$52,39168 claims
Novo NordiskOzempic$1,270$44,35336 claims
Boehringer IngelheimJardiance$874$42,69335 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,146$39,26144 claims
MerckJanuvia$273$26,25528 claims
GSKTrelegy Ellipta$318$15,80813 claims
Johnson & JohnsonXarelto$318$15,37422 claims
Lilly USA, LLCMounjaro$706$12,81312 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$209$10,04412 claims
AbbVieSynthroid$1,514$1,64922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →